References

1. Forth W, Henschler D, Rummel W, Förstermann U, Starke K: Allgemeine und Spezielle Pharmakologie und Toxikologie. 8. Auflage ed, Urban & Fischer Verlag München Jena, 2001.
2. Lamm K, Arnold W: How useful is corticosteroid treatment in cochlear disorders? Otorhinolaryngol Nova 1999;9:203-216.
3. Rarey KE, Luttge WG: Presence of type I and type II/IB receptors for adrenocorticosteroid hormones in the inner ear. Hear Res 1989;41(2-3):217-221.
4. Rarey KE, Curtis LM, ten Cate WJ: Tissue specific levels of glucocorticoid receptor within the rat inner ear. Hear Res 1993;64(2):205-210.
5. Rarey KE, Curtis LM: Receptors for glucocorticoids in the human inner ear. Otolaryngol Head Neck Surg 1996;115(1):38-41.
6. Wangemann P, Schacht J: Homeostatic mechanisms in the Cohlea; In: Dallos P, Popper AN, Fay RR (eds): The Cochlea. New York, Springer, 1996, pp 130-185.
7. Curtis LM, ten Cate WJ, Rarey KE: Dynamics of Na,K-ATPase sites in lat-eral cochlear wall tissues of the rat. Eur Arch Otorhinolaryngol 1993;250(5): 265-270.
8. Erichsen S, Stierna P, Bagger-Sjoback D, Curtis LM, Rarey KE, Schmid W, Hultcrantz M: Distribution of Na,K-ATPase is normal in the inner ear of a mouse with a null mutation of the glucocorticoid receptor. Hear Res 1998;124(1-2):146-154.
9. Fukushima M, Kitahara T, Uno Y, Fuse Y, Doi K, Kubo T: Effects of intratympanic injection of steroids on changes in rat inner ear aquaporin expression. Acta Otolaryngol 2002;122(6):600-606.
10. Fukushima M, Kitahara T, Fuse Y, Uno Y, Doi K, Kubo T: Changes in aquaporin expression in the inner ear of the rat after i.p. injection of steroids. Acta Otolaryngol Suppl 2004;(553):13-18.
11. Mattox DE, Simmons FB: Natural history of sudden sensorineural hearing loss. Ann Otol Rhinol Laryngol 1977;86(4 Pt 1):463-480.
12. Wilson WR, Byl FM, Laird N: The efficacy of steroids in the treatment of idiopathic sudden hearing loss. A double-blind clinical study. Arch Otolaryngol 1980;106(12):772-776.
13. Moskowitz D, Lee KJ, Smith HW: Steroid use in idiopathic sudden sensorineural hearing loss. Laryngoscope 1984;94(5 Pt 1):664-666.
14. Veldman JE, Hanada T, Meeuwsen F: Diagnostic and therapeutic dilem-mas in rapidly progressive sensorineural hearing loss and sudden deafness. A reappraisal of immune reactivity in inner ear disorders. Acta Otolaryngol 1993;113(3):303-306.
15. Alexiou C, Arnold W, Fauser C, Schratzenstaller B, Gloddek B, Fuhrmann S, Lamm K: Sudden sensorineural hearing loss: does application of glucocorticoids make sense? Arch Otolaryngol Head Neck Surg 2001;127(3):253-258.
16. Lamm K, Arnold W: Sind durchblutungsfördernde Massnahmen mit Hämorheologika bei der Behandlung von Innenohrschwerhörigkeiten sinnvoll? Otorhinolayngol Nova 1993;3:285-291.
17. Probst R, Tschopp K, Ludin E, Kellerhals B, Podvinec M, Pfaltz CR: A randomized, double-blind, placebo-controlled study of dextran/pentoxi-fylline medication in acute acoustic trauma and sudden hearing loss. Acta Otolaryngol 1992;112(3):435-443.
18. Kuo ST, Hsu WC, Young YH: Dextran-induced pulmonary edema in patients with sudden deafness. Otol Neurotol 2002;23(5):661-664.
19. Zaytoun GM, Schuknecht HF, Farmer HS: Fatality following the use of low molecular weight dextran in the treatment of sudden deafness. Adv Otorhinolaryngol 1983;31:240-6.
20. Albegger K, Schneeberger R, Franke V, Oberascher G, Miller K: [Itching following therapy with hydroxyethyl starch (HES) in otoneurological diseases]. Wien Med Wochenschr 1992;142(1):1-7.
21. Arzneimittelkommission der deutschen Ärzteschaft: „UAW-News“-International: Hydroxyethylstärke (HES) - Juckreiz. Dt Ärztebl 2000;97(43):A2884.
22. Desloovere C, Knecht R: [Infusion therapy in sudden deafness. Reducing the risk of pruritus after hydroxyethyl starch and maintaining therapeutic success – a prospective randomized study]. Laryngorhinootologie 1995;74(8):468-472.
23. Metze D, Reimann S, Szepfalusi Z, Bohle B, Kraft D, Luger TA: Persistent pruritus after hydroxyethyl starch infusion therapy: a result of long-term storage in cutaneous nerves. Br J Dermatol 1997;136(4):553-559.
24. Murphy M, Carmichael AJ, Lawler PG, White M, Cox NH: The incidence of hydroxyethyl starch-associated pruritus. Br J Dermatol 2001;144(5):973-976.
25. Lamm K, Arnold W: The effect of blood flow promoting drugs on cochlear blood flow, perilymphatic pO(2) and auditory function in the normal and noise-damaged hypoxic and ischemic guinea pig inner ear. Hear Res 2000;141(1-2):199-219.
26. Ohlsen KA, Didier A, Baldwin D, Miller JM, Nuttall AL, Hultcrantz E: Cochlear blood flow in response to dilating agents. Hear Res 1992;58(1):19-25.
27. Lenarz T: [Treatment of sudden deafness with the calcium antagonist nimodipine. Results of a comparative study]. Laryngorhinootologie 1989;68(11):634-637.
28. Mann W, Beck C, Beck C: Calcium antagonists in the treatment of sudden deafness. Arch Otorhinolaryngol 1986;243(3):170-173.
29. Michel O, Matthias R: [Placebo-controlled double-blind study of the treatment of sudden hearing loss with a stable prostacyclin analog]. Laryngorhinootologie 1991;70(5):255-259.

30. Nakashima T, Kuno K, Yanagita N: Evaluation of prostaglandin E1 therapy for sudden deafness. Laryngoscope 1989;99(5):542-546.
31. Ogawa K, Takei S, Inoue Y, Kanzaki J: Effect of prostaglandin E1 on idiopathic sudden sensorineural hearing loss: a double-blinded clinical study. Otol Neurotol 2002;23(5):665-668.
32. Olszewski E, Kostka-Trabka E, Reron E, Grodzinska L, Turek J, mbinska-Kiec A, Bieron K, Basista M, Kedzior A, Slawinski M: [Administration of prostacyclin in sudden deafness. Evaluation with the double blind method]. Otolaryngol Pol 1990;44(1):62-65.
33. Scherer EQ, Herzog M, Wangemann P: Endothelin-1-induced vasospasms of spiral modiolar artery are mediated by rho-kinase-induced Ca(2+) sensitization of contractile apparatus and reversed by calcitonin gene-related Peptide. Stroke 2002;33(12):2965-2971.
34. Bárány R: Die Beeinflussung des Ohrensausens durch intravenös injizierte Lokalanästhetika. Acta Otolaryngol 1935;23:201-207.
35. Laurikainen E, Lin X, Nuttall AL, Dolan DF: The mechanism and site of action of lidocaine hydrochloride in guinea pig inner ear. Acta Otolaryngol 1997;117(4):523-528.
36. Lenarz T: Treatment of tinnitus with lidocaine and tocainide. Scand Audiol Suppl 1986;26:49-51.:49-51.
37. Kronenberg J, Almagor M, Bendet E, Kushnir D: Vasoactive therapy versus placebo in the treatment of sudden hearing loss: a double-blind clinical study. Laryngoscope 1992;102(1):65-68.
38. Moser T, Beutner D: Kinetics of exocytosis and endocytosis at the cochlear inner hair cell afferent synapse of the mouse. Proc Natl Acad Sci U S A 2000;97(2):883-888.
39. Platzer J, Engel J, Schrott-Fischer A, Stephan K, Bova S, Chen H, Zheng H, Striessnig J: Congenital deafness and sinoatrial node dysfunction in mice lacking class D L-type Ca2+ channels. Cell 2000;102(1):89-97.
40. Engel J, Michna M, Platzer J, Striessnig J: Calcium channels in mouse hair cells: function, properties and pharmacology. Adv Otorhinolaryngol 2002;59:35-41.
41. Boettcher FA, Caldwell RK, Gratton MA, White DR, Miles LR: Effects of nimodipine on noise-induced hearing loss. Hear Res 1998;121(1-2):139-146.
42. Vollrath M, Marangos N, Hesse G: [Dehydration therapy in low tone hearing loss. An alternative to rheologic therapy?]. HNO 1990;38(4):154-157.
43. Evans P, Halliwell B: Free radicals and hearing. Cause, consequence, and criteria. Ann N Y Acad Sci 1999;884:19-40.
44. Kopke R, Allen KA, Henderson D, Hoffer M, Frenz D, Van de Water TR: A radical demise. Toxins and trauma share common pathways in hair cell death. Ann N Y Acad Sci 1999;884:171-191.
45. Miller JM, Schacht J, Altschuler R: Prevention of noise-induced hearing loss; In: Henderson D, Prasher D, Kopke R., Hamernik RP (eds): Noise induced hearing loss: basic mechanisms, prevention and control. London, NRN publications, 2001, pp 215-230.
46. Lautermann J, Crann SA, McLaren J, Schacht J: Glutathione-dependent antioxidant systems in the mammalian inner ear: effects of aging, ototoxic drugs and noise. Hear Res 1997;114(1-2):75-82.
47. Gilgun-Sherki Y, Rosenbaum Z, Melamed E, Offen D: Antioxidant therapy in acute central nervous system injury: current state 17. Pharmacol Rev 2002;54(2):271-284.
48. Eidelman RS, Hollar D, Hebert PR, Lamas GA, Hennekens CH: Randomized trials of vitamin E in the treatment and prevention of cardiovascular disease. Arch Intern Med 2004;164(14):1552-1556.
49. Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ: Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet 2003;361(9374):2017-2023.
50. Packer L: alpha-Lipoic acid: a metabolic antioxidant which regulates NF-kappa B signal transduction and protects against oxidative injury. Drug Metab Rev 1998;30(2):245-275.
51. Ziegler D, Nowak H, Kempler P, Vargha P, Low PA: Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med 2004;21(2):114-121.
52. Conlon BJ, Aran JM, Erre JP, Smith DW: Attenuation of aminoglycoside-induced cochlear damage with the metabolic antioxidant alpha-lipoic acid. Hear Res 1999;128(1-2):40-44.
53. Rybak LP, Husain K, Whitworth C, Somani SM: Dose dependent protection by lipoic acid against cisplatin-induced ototoxicity in rats: antioxidant defense system. Toxicol Sci 1999;47(2):195-202.
54. Weinaug P: [Treatment of acute inner ear diseases (sudden deafness and vestibular disorder) with meclofenoxate and acetylsalicylic acid]. HNO 1988;36(6):226-229.
55. Kubo T, Matsunaga T, Asai H, Kawamoto K, Kusakari J, Nomura Y, Oda M, Yanagita N, Niwa H, Uemura T, .: Efficacy of defibrinogenation and steroid therapies on sudden deafness. Arch Otolaryngol Head Neck Surg 1988;114(6):649-652.
56. Suzuki H, Furukawa M, Kumagai M, Takahashi E, Matsuura K, Katori Y, Shimomura A, Kobayashi T: Defibrinogenation therapy for idiopathic sudden sensorineural hearing loss in comparison with high-dose steroid therapy. Acta Otolaryngol 2003;123(1):46-50.
57. Shiraishi T, Kubo T, Matsunaga T: Chronological study of recovery of sudden deafness treated with defibrinogenation and steroid therapies. Acta Otolaryngol 1991;111(5):867-871.
58. Hagen R: [Fibrinolytic therapy in sudden deafness with recombinant tissue-type plasminogen activator. Hemorheologic

and therapeutic effects]. Laryngorhinootologie 1991;70(7):353-358.
59. Klemm E, Altmann E, Lange O: [Rheologic problems of microcirculation and consequences of drug therapy for sudden deafness]. Laryngol Rhinol Otol (Stuttg) 1983;62(2):62-64.
60. Lamm K, Arnold W: Noise-induced cochlear hypoxia is intensity dependent, correlates with hearing loss and precedes reduction of cochlear blood flow. Audiol Neurootol 1996;1(3):148-160.
61. Lamm C, Walliser U, Schumann K, Lamm K: [Oxygen partial pressure measurements in the perilymph and scala tympani in normo- and hyperbaric conditions. An animal experiment study]. HNO 1988;36(9):363-366.
62. Lamm K, Lamm C, Arnold W: Effect of isobaric oxygen versus hyperbaric oxygen on the normal and noise-damaged hypoxic and ischemic guinea pig inner ear. Adv Otorhinolaryngol 1998;54:59-85.:59-85.
63. Lamm K, Lamm H, Arnold W: Effect of hyperbaric oxygen therapy in comparison to conventional or placebo therapy or no treatment in idiopathic sudden hearing loss, acoustic trauma, noise-induced hearing loss and tinnitus. A literature survey. Adv Otorhinolaryngol 1998;54:86-99.:86-99.
64. Kestler M, Strutz J, Heiden C: [Hyperbaric oxygenation in early treatment of sudden deafness]. HNO 2001;49(9):719-723.
65. Fattori B, Berrettini S, Casani A, Nacci A, De VA, De IG: Sudden hypoacusis treated with hyperbaric oxygen therapy: a controlled study. Ear Nose Throat J 2001;80(9):655-660.
66. Racic G, Maslovara S, Roje Z, Dogas Z, Tafra R: Hyperbaric oxygen in the treatment of sudden hearing loss. ORL J Otorhinolaryngol Relat Spec 2003;65(6):317-320.
67. Aslan I, Oysu C, Veyseller B, Baserer N: Does the addition of hyperbaric oxygen therapy to the conventional treatment modalities influence the outcome of sudden deafness? Otolaryngol Head Neck Surg 2002;126(2):121-126.
68. Topuz E, Yigit O, Cinar U, Seven H: Should hyperbaric oxygen be added to treatment in idiopathic sudden sensorineural hearing loss? Eur Arch Otorhinolaryngol 2004;261(7):393-396.
69. Inci E, Erisir F, Ada M, Ozturk O, Guclu E, Oktem F, Toprak M: [Hyperbaric oxygen treatment in sudden hearing loss after unsuccessful medical treatment]. Kulak Burun Bogaz Ihtis Derg 2002;9(5):337-341.
70. Kau RJ, Sendtner-Gress K, Ganzer U, Arnold W: Effectiveness of hyperbaric oxygen therapy in patients with acute and chronic cochlear disorders. ORL J Otorhinolaryngol Relat Spec 1997;59(2):79-83.
71. Murakawa T, Kosaka M, Mori Y, Fukazawa M, Misaki K: [Treatment of 522 patients with sudden deafness performed oxygenation at high pressure]. Nippon Jibiinkoka Gakkai Kaiho 2000;103(5):506-515.
72. Nakashima T, Fukuta S, Yanagita N: Hyperbaric oxygen therapy for sudden deafness. Adv Otorhinolaryngol 1998;54:100-9.:100-109.
73. Kanemaru S, Fukushima H, Nakamura H, Tamaki H, Fukuyama Y, Tamura Y: Alpha-Interferon for the treatment of idiopathic sudden sensorineural hearing loss. Eur Arch Otorhinolaryngol 1997;254(3):158-162.
74. Puel JL, Ruel J, Gervais dC, Pujol R: Excitotoxicity and repair of cochlear synapses after noise-trauma induced hearing loss. Neuroreport 1998;9(9):2109-2114.
75. Oestreicher E, Arnold W, Felix D: Neurotransmission of the cochlear inner hair cell synapse--implications for inner ear therapy. Adv Otorhinolaryngol 2002;59:131-139.
76. Puel JL, Ruel J, Guitton M, Pujol R: The inner hair cell afferent/efferent synapses revisited: a basis for new therapeutic strategies. Adv Otorhinolaryngol 2002;59:124-130.
77. Ehrenberger K, Felix D: Caroverine depresses the activity of cochlear glutamate receptors in guinea pigs: in vivo model for drug-induced neuroprotection? 7. Neuropharmacology 1992;31(12):1259-1263.
78. Oestreicher E, Ehrenberger K, Felix D: Different action of memantine and caroverine on glutamatergic transmission in the mammalian cochlea. Adv Otorhinolaryngol 2002;59:18-25.
79. Plontke S, Zenner HP: Current Aspects of Hearing Loss from Occupational and Leisure Noise. In: Schultz-Coulon HJ (ed.). Current Topics in Otorhinolaryngology –Head and Neck Surgery: Environmental and Occupational Health Disorders. 2004. Videel, Niebuel, Germany.
80. Haupt H, Scheibe F, Mazurek B: Therapeutic efficacy of magnesium in acoustic trauma in the guinea pig. ORL J Otorhinolaryngol Relat Spec 2003;65(3):134-139.
81. Joachims Z, Babisch W, Ising H, Gunther T, Handrock M: Dependence of noise-induced hearing loss upon perilymph magnesium concentration. J Acoust Soc Am 1983;74(1):104-108.
82. Scheibe F, Haupt H, Ising H, Cherny L: Therapeutic effect of parenteral magnesium on noise-induced hearing loss in the guinea pig. Magnes Res 2002;15(1-2):27-36.
83. Kallinen J, Laurikainen E, Laippala P, Grenman R: Sudden deafness: a comparison of anticoagulant therapy and carbogen inhalation therapy. Ann Otol Rhinol Laryngol 1997;106(1):22-26.
84. Rahko T, Kotti V: Comparison of carbogen inhalation and intravenous heparin infusion therapies in idiopathic sudden sensorineural hearing loss. Acta Otolaryngol Suppl 1997;529:86-7.:86-87.
85. Gutmann R, Mees K: [Piracetam infusions in acute tinnitus and sudden deafness]. Fortschr Med 1995;113(18):288-290.
86. Birks J, Grimley EV, Van DM: Ginkgo biloba for cognitive impairment and de-

mentia. Cochrane Database Syst Rev 2002;(4):CD003120.
87. Ahlemeyer B, Krieglstein J: Neuroprotective effects of Ginkgo biloba extract. Cell Mol Life Sci 2003;60(9):1779-1792.
88. Hoffmann F, Beck C, Schutz A, Offermann P: [Ginkgo extract EGb 761 (tenobin)/HAES versus naftidrofuryl (Dusodril)/HAES. A randomized study of therapy of sudden deafness]. Laryngorhinootologie 1994;73(3):149-152.
89. Reisser CH, Weidauer H: Ginkgo biloba extract EGb 761 or pentoxifylline for the treatment of sudden deafness: a randomized, reference-controlled, double-blind study. Acta Otolaryngol 2001;121(5):579-584.
90. Burschka MA, Hassan HA, Reineke T, van BL, Caird DM, Mosges R: Effect of treatment with Ginkgo biloba extract EGb 761 (oral) on unilateral idiopathic sudden hearing loss in a prospective randomized double-blind study of 106 outpatients. Eur Arch Otorhinolaryngol 2001;258(5):213-219.
91. Hilton M, Stuart E: Ginkgo biloba for tinnitus. Cochrane Database Syst Rev 2004;(2):CD003852.
92. Meier R, Tschopp K, Podvinec M, Grossenbacher R, Ermanni D, Probst R: [Results of a prospective open study of therapy of sudden deafness with flunarizine]. Laryngorhinootologie 1993;72(6):291-294.
93. Harris JP, Weisman MH, Derebery JM, Espeland MA, Gantz BJ, Gulya AJ, Hammerschlag PE, Hannley M, Hughes GB, Moscicki R, Nelson RA, Niparko JK, Rauch SD, Telian SA, Brookhouser PE: Treatment of corticosteroid-responsive autoimmune inner ear disease with methotrexate: a randomized controlled trial. JAMA 2003;290(14):1875-1883.
94. Chole RA, McKenna M: Pathophysiology of otosclerosis. Otol Neurotol 2001;22(2):249-257.
95. Liu JM, Ma L, He WP: [Therapeutic effect of puerarin therapy on sudden deafness]. Di Yi Jun Yi Da Xue Xue Bao 2002;22(11):1044-1045.
96. Bibel M, Barde YA: Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system 1. Genes Dev 2000;14(23):2919-2937.
97. Paasche G, Gibson P, Averbeck T, Becker H, Lenarz T, Stover T: Technical report: modification of a cochlear implant electrode for drug delivery to the inner ear. 363. Otol Neurotol 2003;24(2):222-227.
98. Pirvola U, Xing-Qun L, Virkkala J, Saarma M, Murakata C, Camoratto AM, Walton KM, Ylikoski J: Rescue of hearing, auditory hair cells, and neurons by CEP-1347/KT7515, an inhibitor of c-Jun N-terminal kinase activation. 27. J Neurosci 2000;20(1):43-50.
99. Wang J, Ding D, Shulman A, Stracher A, Salvi RJ: Leupeptin protects sensory hair cells from acoustic trauma. Neuroreport 1999;10(4):811-816.
100. Wang J, Van De Water TR, Bonny C, de Ribaupierre F, Puel JL, Zine A: A peptide inhibitor of c-Jun N-terminal kinase protects against both aminoglycoside and acoustic trauma-induced auditory hair cell death and hearing loss. J Neurosci 2003;23(24):8596-8607.
101. Scarpidis U, Madnani D, Shoemaker C, Fletcher CH, Kojima K, Eshraghi AA, Staecker H, Lefebvre P, Malgrange B, Balkany TJ, Van De Water TR: Arrest of apoptosis in auditory neurons: implications for sensorineural preservation in cochlear implantation. Otol Neurotol 2003;24(3):409-417.
102. Gentherapie; in: Brockhaus - die Enzyklopädie. F.A. Brockhaus Leipzig Mannheim, 1997, pp 340.
103. Probst FJ, Fridell RA, Raphael Y, Saunders TL, Wang A, Liang Y, Morell RJ, Touchman JW, Lyons RH, Noben-Trauth K, Friedman TB, Camper SA: Correction of deafness in shaker-2 mice by an unconventional myosin in a BAC transgene. Science 1998;280(5368):1444-1447.
104. Mburu P, Mustapha M, Varela A, Weil D, El-Amraoui A, Holme RH, Rump A, Hardisty RE, Blanchard S, Coimbra RS, Perfettini I, Parkinson N, Mallon AM, Glenister P, Rogers MJ, Paige AJ, Moir L, Clay J, Rosenthal A, Liu XZ, Blanco G, Steel KP, Petit C, Brown SD: Defects in whirlin, a PDZ domain molecule involved in stereocilia elongation, cause deafness in the whirler mouse and families with DFNB31. Nat Genet 2003;34(4):421-428.
105. Avraham KB, Raphael Y: Prospects for gene therapy in hearing loss. J Basic Clin Physiol Pharmacol 2003;14(2):77-83.
106. Lalwani AK, Jero J, Mhatre AN: Current issues in cochlear gene transfer. Audiol Neurootol 2002;7(3):146-151.
107. Minoda R, Izumikawa M, Kawamoto K, Raphael Y: Strategies for replacing lost cochlear hair cells. Neuroreport 2004;15(7):1089-1092.
108. Pfister M, Lowenheim H: Gentherapie des Innenohres. Medizinische Genetik 2002;14(1). 53-57.
109. Cotanche DA: Structural recovery from sound and aminoglycoside damage in the avian cochlea. Audiol Neurootol 1999;4(6):271-285.
110. Smolders JW: Functional recovery in the avian ear after hair cell regeneration. Audiol Neurootol 1999;4(6):286-302.
111. Lowenheim H: Grundlagen der in vivo Regeneration im Kopf-Halsbereich. Laryngorhinootologie 2002;Suppl 1:1-23.
112. Ryan AF: The cell cycle and the development and regeneration of hair cells. Curr Top Dev Biol 2003;57:449-66.:449-466.
113. Bermingham NA, Hassan BA, Price SD, Vollrath MA, Ben-Arie N, Eatock RA, Bellen HJ, Lysakowski A, Zoghbi HY: Math1: an essential gene for the generation of inner ear hair cells. Science 1999;284(5421):1837-1841.
114. Kawamoto K, Ishimoto S, Minoda R, Brough DE, Raphael Y: Math1 gene transfer generates new cochlear hair cells in mature guinea pigs in vivo. J Neurosci 2003;23(11):4395-4400.

115. Forge A, Li L, Corwin JT, Nevill G: Ultrastructural evidence for hair cell regeneration in the mammalian inner ear. Science 1993;259(5101):1616-1619.
116. Warchol ME, Lambert PR, Goldstein BJ, Forge A, Corwin JT: Regenerative proliferation in inner ear sensory epithelia from adult guinea pigs and humans. Science 1993;259(5101):1619-1622.
117. Shou J, Zheng JL, Gao WQ: Robust generation of new hair cells in the mature mammalian inner ear by adenoviral expression of Hath1. Mol Cell Neurosci 2003;23(2):169-179.
118. Li H, Corrales CE, Edge A, Heller S: Stem cells as therapy for hearing loss. Trends Mol Med 2004;10(7):309-315.
119. Parker MA, Cotanche DA: The potential use of stem cells for cochlear repair. Audiol Neurootol 2004;9(2):72-80.
120. Li H, Roblin G, Liu H, Heller S: Generation of hair cells by stepwise differentiation of embryonic stem cells. Proc Natl Acad Sci U S A 2003;100(23):13495-13500.
121. Li H, Liu H, Heller S: Pluripotent stem cells from the adult mouse inner ear. Nat Med 2003;9(10):1293-1299.
122. Goycoolea MV: Clinical aspects of round window membrane permeability under normal and pathological conditions. Acta Otolaryngol 2001;121(4):437-447.
123. Ersner MS, Spiegel EA, Alexander MH: Transtympanic injection of anesthetics for the treatment of Menièr's Syndrome. Arch Otorhinolaryngol 1951;(54):43-52.
124. Völger G: Beseitigung von Labyrinthliquordruckstörungen bei dem Menièrschen Symptomkomplex durch das Hyaluronidasepräparat Kinetin. HNO 1952;3(5):142-147.
125. Chandrasekhar SS: Intratympanic dexamethasone for sudden sensorineural hearing loss: clinical and laboratory evaluation. Otol Neurotol 2001;22(1):18-23.
126. Gianoli GJ, Li JC: Transtympanic steroids for treatment of sudden hearing loss. Otolaryngol Head Neck Surg 2001;125(3):142-146.
127. Gouveris H, Selivanova O, Mann W. Intratympanic dexamethasone with hyaluronic acid in the treatment of idiopathic sudden sensorineural hearing loss after failure of intravenous steroid and vasoactive therapy. Eur Arch Otorhinolaryngol. 2005;262(2):131-4.
128. Ho HG, Hung-Ching L, Min-Tsan S, Cheng-Chien Y, Hsun-Tien T: Effectiveness of intratympanic dexamethasone injection in sudden-deafness patients as salvage treatment. Laryngoscope 2004;114(7):1184-1189.
129. Hoffmann KK, Silverstein H: Inner ear perfusion: indications and applications. Curr Opin Otolaryngol Head Neck Surg 2003;11(5):334-339.
130. Kopke RD, Hoffer ME, Wester D, O'Leary MJ, Jackson RL: Targeted topical steroid therapy in sudden sensorineural hearing loss. Otol Neurotol 2001;22(4):475-479.
131. Lefebvre PP, Staecker H: Steroid perfusion of the inner ear for sudden sensorineural hearing loss after failure of conventional therapy: a pilot study. Acta Otolaryngol 2002;122(7):698-702.
132. Parnes LS, Sun AH, Freeman DJ: Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application. Laryngoscope 1999;109(7 Pt 2):1-17.
133. Itoh A, Sakata E: Treatment of vestibular disorders. Acta Otolaryngol Suppl 1991;481:617-623.
134. Sennaroglu L, Dini FM, Sennaroglu G, Gursel B, Ozkan S: Transtympanic dexamethasone application in Meniere's disease: an alternative treatment for intractable vertigo. J Laryngol Otol 1999;113(3):217-221.
135. Shea JJ, Jr., Ge X: Dexamethasone perfusion of the labyrinth plus intravenous dexamethasone for Meniere's disease. Otolaryngol Clin North Am 1996;29(2):353-358.
136. Silverstein H, Isaacson JE, Olds MJ, Rowan PT, Rosenberg S: Dexamethasone inner ear perfusion for the treatment of Meniere's disease: a prospective, randomized, double-blind, crossover trial. Am J Otol 1998;19(2):196-201.
137. Cesarani A, Capobianco S, Soi D, Giuliano DA, Alpini D: Intratympanic dexamethasone treatment for control of subjective idiopathic tinnitus: our clinical experience. Int Tinnitus J 2002;8(2):111-114.
138. Coles RR, Thompson AC, O'Donoghue GM: Intra-tympanic injections in the treatment of tinnitus. Clin Otolaryngol 1992;17(3):240-242.
139. Sakata E, Ito Y, Itoh A: Clinical Experiences of Steroid Targeting Therapy to Inner Ear for Control of Tinnitus. Int Tinnitus J 1997;3(2):117-121.
140. Shulman A, Goldstein B: Intratympanic drug therapy with steroids for tinnitus control: a preliminary report. Int Tinnitus J 2000;6(1):10-20.
141. Silverstein H, Choo D, Rosenberg SI, Kuhn J, Seidman M, Stein I: Intratympanic steroid treatment of inner ear disease and tinnitus (preliminary report). Ear Nose Throat J 1996;75(8):468-71, 474, 476.
142. Ristow W: Zur Behandlung der Menière-Krankheit mittels temporärer Labyrinthanästhesie. Z Laryngol Rhinol 1968;(6):442-448.
143. Schwab B, Lenarz T, Heermann R: [Use of the Round Window micro Cath for Inner Ear Therapy - Results of a Placebo-Controlled, Prospective Study on Chronic Tinnitus]. Laryngorhinootologie 2004;83(3):164-172.
144. Chen Z, Ulfendahl M, Ruan R, Tan L, Duan M: Acute treatment of noise trauma with local caroverine application in the guinea pig. Acta Otolaryngol 2003;123(8):905-909.
145. Hight NG, McFadden SL, Henderson D, Burkard RF, Nicotera T: Noise-induced hearing loss in chinchillas pre-treated with glutathione monoethylester and R-PIA. Hear Res 2003;179(1-2):21-32.
146. Keithley EM, Ma CL, Ryan AF, Louis JC, Magal E: GDNF protects the cochlea

against noise damage. Neuroreport 1998;9(10):2183-2187.
147. Wang J, Dib M, Lenoir M, Vago P, Eybalin M, Hameg A, Pujol R, Puel JL: Riluzole rescues cochlear sensory cells from acoustic trauma in the guinea-pig. Neuroscience 2002;111(3):635-648.
148. Korver KD, Rybak LP, Whitworth C, Campbell KM: Round window application of D-methionine provides complete cisplatin otoprotection. Otolaryngol Head Neck Surg 2002;126(6):683-689.
149. Li G, Frenz DA, Brahmblatt S, Feghali JG, Ruben RJ, Berggren D, Arezzo J, Van De Water TR: Round window membrane delivery of L-methionine provides protection from cisplatin ototoxicity without compromising chemotherapeutic efficacy. Neurotoxicology 2001;22(2):163-176.
150. Dazert S, Battaglia A, Ryan AF: Transfection of neonatal rat cochlear cells in vitro with an adenovirus vector. Int J Dev Neurosci 1997;15(4-5):595-600.
151. Lalwani AK, Walsh BJ, Reilly PG, Muzyczka N, Mhatre AN: Development of in vivo gene therapy for hearing disorders: introduction of adeno-associated virus into the cochlea of the guinea pig. Gene Ther 1996;3(7):588-592.
152. Raphael Y, Frisancho JC, Roessler BJ: Adenoviral-mediated gene transfer into guinea pig cochlear cells in vivo. Neurosci Lett 1996;207(2):137-141.
153. Stover T, Yagi M, Raphael Y: Cochlear gene transfer: round window versus cochleostomy inoculation. Hear Res 1999;136(1-2):124-130.
154. Bachmann G, Su J, Zumegen C, Wittekindt C, Michel O: Permeabilität der runden Fenstermembran für Prednisolon-21-Hydrogensuccinat. HNO 2001;49(7):538-542.
155. Chen Z, Duan M, Lee H, Ruan R, Ulfendahl M: Pharmacokinetics of caroverine in the inner ear and its effects on cochlear function after systemic and local administrations in Guinea pigs. Audiol Neurootol 2003;8(1):49-56.
156. Hibi T, Suzuki T, Nakashima T: Perilymphatic concentration of gentamicin administered intratympanically in guinea pigs. Acta Otolaryngol 2001;121:336-341.
157. Hoffer ME, Balough B, Henderson J, DeCicco M, Wester D, O'Leary MJ, Kopke R: Use of sustained release vehicles in the treatment of Meniere's disease. Otolaryngol Clin North Am 1997;30(6):1159-1166.
158. Tran Ba HP, Bernard P, Schacht J: Kinetics of gentamicin uptake and release in the rat. Comparison of inner ear tissues and fluids with other organs. J Clin Invest 1986;77(5):1492-1500.
159. Gallant C, Kenny P: Oral glucocorticoids and their complications. A review. J Am Acad Dermatol 1986;14(2 Pt 1):161-177.
160. Lange G, Maurer J, Mann W: Long-term results after interval therapy with intratympanic gentamicin for Meniere's disease. Laryngoscope 2004;114(1):102-105.
161. Thomsen J, Charabi S, Tos M: Preliminary results of a new delivery system for gentamicin to the inner ear in patients with Meniere's disease. Eur Arch Otorhinolaryngol 2000;257(7):362-365.
162. Schoendorf J, Neugebauer P, Michel O: Continuous intratympanic infusion of gentamicin via a microcatheter in Meniere's disease. Otolaryngol Head Neck Surg 2001;124(2):203-207.
163. Salt AN, Ma Y: Quantification of solute entry into cochlear perilymph through the round window membrane. Hear Res 2001;154(1-2):88-97.
164. Salt AN: Simulation of methods for drug delivery to the cochlear fluids. Adv Otorhinolaryngol 2002;59:140-148.
165. Hobbie RK: Transport in an Infinite Medium; Intermediate Physics fpr Medicine and Biology. Springer New York, 1997, pp 85-90.
166. Plontke SK, Salt AN: Quantitative interpretation of corticosteroid pharmakokinetics in innner ear fluids using computer simulations. Hear Res 2003;182:34-42.
167. Chandrasekhar SS, Rubinstein RY, Kwartler JA, Gatz M, Connelly PE, Huang E, Baredes S: Dexamethasone pharmacokinetics in the inner ear: comparison of route of administration and use of facilitating agents. Otolaryngol Head Neck Surg 2000;122(4):521-528.
168. Selivanova O, Maurer J, Ecke U, Mann WJ: [The effects of Streptolysin-O and sodium hyaluronate on the permeability of the round window membrane in guinea pigs--an electrophysiologic study]. Laryngorhinootologie 2003;82(4):235-239.
169. Ohyama K, Salt AN, Thalmann R: Volume flow rate of perilymph in the guinea-pig cochlea. Hear Res 1988;35(2-3):119-129.
170. Salt AN, Ohyama K, Thalmann R: Radial communication between the perilymphatic scalae of the cochlea. II: Estimation by bolus injection of tracer into the sealed cochlea. Hear Res 1991;56(1-2):37-43.
171. Salt AN, Thalmann R, Marcus DC, Bohne BA: Direct measurement of longitudinal endolymph flow rate in the guinea pig cochlea. Hear Res 1986;23(2):141-151.
172. Plontke SK, Wood AW, Salt AN: Analysis of gentamicin kinetics in fluids of the inner ear with round window administration. Otol Neurotol 2002;23(6):967-974.
173. Saijo S, Kimura RS: Distribution of HRP in the inner ear after injection into the middle ear cavity
174. 388. Acta Otolaryngol 1984;97(5-6):593-610.
175. Hoffer ME, Allen K, Kopke RD, Weisskopf P, Gottshall K, Wester D: Transtympanic versus sustained-release administration of gentamicin: kinetics, morphology, and function. Laryngoscope 2001;111(8):1343-1357.
176. Laurell G, Teixeira M, Sterkers O, Bagger-Sjoback D, Eksborg S, Lidman O, Ferrary E: Local administration of anti-

oxidants to the inner ear. Kinetics and distribution. Hear Res 2002;173(1-2):198-209.
177. Thorne M, Salt AN, DeMott JE, Henson MM, Henson OW, Jr., Gewalt SL: Cochlear fluid space dimensions for six species derived from reconstructions of three-dimensional magnetic resonance images. Laryngoscope 1999;109(10):1661-1668.
178. Hara A, Salt AN, Thalmann R: Perilymph composition in scala tympani of the cochlea: influence of cerebrospinal fluid. Hear Res 1989;42(2-3):265-271.
179. Salt AN, Kellner C, Hale S: Contamination of perilymph samples from the basal cochlear fluid with cerebrospinal fluid. Hear Res 2003;(182):23-33.
180. Scheibe F, Haupt H, Bergmann K: On sources of error in the biochemical study of perilymph (guinea pig). Arch Otorhinolaryngol 1984;240:43-48.
181. Hahn H, Plontke SK, Zenner HP, Salt AN: Microdialysis for studying pharmacokinetics in the inner ear and interpretation of results using a finite element model. Assoc Res Otolaryngol Abs 2004;65.
182. Lange G: [27 years experiences with transtympanic aminoglycoside treatment of Meniere‘s disease]. Laryngo-rhinootologie 1995;74(12):720-723.
183. Schuknecht HF: Ablation therapy in the management of Meniere‘s disease. Acta Otolaryngol 1957;47(Suppl 132):1-42.
184. Arriaga MA, Goldman S: Hearing results of intratympanic steroid treatment of endolymphatic hydrops. Laryngoscope 1998;108(11 Pt 1):1682-1685.
185. Kroath F: Transtympanale Injektion zur Behandlung des Menièreschen Syndroms. Z Laryngol Rhinol 1960;39:190.
186. Silverstein H, Arruda J, Rosenberg SI, Deems D, Hester TO: Direct round window membrane application of gentamicin in the treatment of Meniere‘s disease. Otolaryngol Head Neck Surg 1999;120(5):649-655.
187. Alzamil KS, Linthicum FH, Jr.: Extraneous round window membranes and plugs: possible effect on intratympanic therapy. Ann Otol Rhinol Laryngol 2000;109(1):30-32.
188. Plontke SK, Plinkert PK, Plinkert B, Koitschev A, Zenner HP, Lowenheim H: Transtympanic endoscopy for drug delivery to the inner ear using a new microendoscope. Adv Otorhinolaryngol 2002;59:149-155.
189. Silverstein H: Use of a new device, the MicroWick, to deliver medication to the inner ear. Ear Nose Throat J 1999;78(8):595-8, 600.
190. Lehner R, Brugger H, Maassen MM, Zenner HP: A totally implantable drug delivery system for local therapy of the middle and inner ear. Ear Nose Throat J 1997;76(8):567-570.
191. Praetorius M, Limberger A, Muller M, Lehner R, Schick B, Zenner HP, Plinkert P, Knipper M: A novel microperfusion system for the long-term local supply of drugs to the inner ear: implantation and function in the rat model. Audiol Neurootol 2001;6(5):250-258.
192. Endo T, Nakagawa T, Kita T, Iguchi F, Kim TS, Tamura T, Naito Y, Tabata Y, Ito J: A novel drug delivery system into the innner ear. Abs Assoc Res ORL 2004;27:64.
193. Arnold W, Senn P, Hennig M, Michaelis C, Deingruber K, Scheler R, Steinhoff HJ, Riphagen F, Lamm K. Novel slow- and fast- type drug release round-window microimplants for local drug application to the cochlea. an experimental study in guinea pigs. Audiol Neurootol 2005; 10: 53-63
194. Plontke, S., Lowenheim, H., Preyer, S., Leins, S., Koitschev, A., Zimmermann, R., and Zenner, H. P. Outcomes research analysis of continuous intratympanic glucocorticoid delivery in patients with acute severe to profound hearing loss: basis for planning of randomized controlled trials. Acta Otorhinolaryngologica 2005; [Epub ahead of print]
195. Lautermann J, Sudhoff H, Junker R. Transtympanic corticoid therapy for acute profound hearing loss. Eur Arch Otorhinolaryngol. 2005; [Epub ahead of print]
196. Suckfull M, Thiery J, Schorn K, Kastenbauer E, Seidel D: Clinical utility of LDL-apheresis in the treatment of sudden hearing loss: a prospective, randomized study. Acta Otolaryngol 1999;119(7):763-766.
197. Suckfull M: Fibrinogen and LDL apheresis in treatment of sudden hearing loss: a randomised multicentre trial. Lancet 2002;360(9348):1811-1817.
198. Ullrich H, Kleinjung T, Steffens T, Jacob P, Schmitz G, Strutz J: Improved treatment of sudden hearing loss by specific fibrinogen aphaeresis. J Clin Apheresis 2004;19(2):71-78.
199. Hallett M: Transcranial magnetic stimulation and the human brain. Nature 2000;406(6792):147-150.
200. Chen R, Classen J, Gerloff C, Celnik P, Wassermann EM, Hallett M, Cohen LG: Depression of motor cortex excitability by low-frequency transcranial magnetic stimulation. Neurology 1997;48(5):1398-1403.
201. Plewnia C, Bartels M, Gerloff C: Transient suppression of tinnitus by transcranial magnetic stimulation. Ann Neurol 2003;53(2):263-266.
202. Muhlnickel W, Elbert T, Taub E, Flor H: Reorganization of auditory cortex in tinnitus. Proc Natl Acad Sci U S A 1998;95(17):10340-10343.
203. Rauschecker JP: Auditory cortical plasticity: a comparison with other sensory systems. Trends Neurosci 1999;22(2):74-80.
204. Lockwood AH, Wack DS, Burkard RF, Coad ML, Reyes SA, Arnold SA, Salvi RJ: The functional anatomy of gaze-evoked tinnitus and sustained lateral gaze. Neurology 2001;56(4):472-480.
205. Moller AR: Similarities between severe tinnitus and chronic pain. J Am Acad Audiol 2000;11(3):115-124.
206. Hoffman RE, Cavus I: Slow transcranial magnetic stimulation, long-term

depotentiation, and brain hyperexcitability disorders. Am J Psychiatry 2002;159(7):1093-1102.
207. Eichhammer P, Langguth B, Marienhagen J, Kleinjung T, Hajak G: Neuronavigated repetitive transcranial magnetic stimulation in patients with tinnitus: a short case series. Biol Psychiatry 2003;54(8):862-865.
208. Plewnia C, Kammer T, Gerloff C: Comment on „Neuronavigated repetitive transcranial magnetic stimulation in patients with tinnitus: a short case series“. Biol Psychiatry 2004;55(11):1117-1118.
209. Okusa M, Shiraishi T, Kubo T, Matsunaga T: Tinnitus suppression by electrical promontory stimulation in sensorineural deaf patients. Acta Otolaryngol Suppl 1993;501:54-8.:54-58.
210. DeRidder D., DeMulder G., Walsh V, Muggleton N, Sunaert S, Moller A: Magnetic and electrical stimulation of the auditory cortex for intractable tinnitus. Case report. J Neurosurg 2004;100(3):560-564.
211. Jastreboff PJ, Hazell JW: A neurophysiological approach to tinnitus: clinical implication. 10. Br J Audiol 1993;27(1):7-17.
212. Jastreboff PJ, Jastreboff MM: Tinnitus retraining therapy for patients with tinnitus and decreased sound tolerance. 13. Otolaryngol Clin North Am 2003;36(2):321-336.
213. Kroener-Herwig B, Biesinger E, Gerhards F, Goebel G, Verena GK, Hiller W: Retraining therapy for chronic tinnitus. A critical analysis of its status. 17. Scand Audiol 2000;29(2):67-78.
214. von Wedel H, von Wedel UC: [An assessment of tinnitus retraining therapy]. 16. HNO 2000;48(12):887-901.
215. Goebel G, Rubler D, Stepputat F, Hiller W, Heuser J, Fichter MM: Controlled prospective study of tinnitus retraining therapy compared to tinnitus coping therapy and broad-band noise generator therapy.; In: Hazell JW (ed): Proceedings of the Sixth International Tinnitus Seminar. Cambridge, 1999, pp 302-306.
216. Delb W, D‘Amelio R, Boisten CJ, Plinkert PK: [Evaluation of the tinnitus retraining therapy as combined with a cognitive behavioral group therapy]. HNO 2002;50(11):997-1004.
217. McKinney CJ, Hazell JW, Graham RL: An evaluation of the TRT method; In: Hazell JW (ed): Proceedings of the Sixth International Tinnitus Seminar. Cambridge, 1999, pp 99-105.
218. Schilter B, Jager B, Heermann R, Lamprecht F: [Drug and psychological therapies in chronic subjective tinnitus. Meta-analysis of therapeutic effectiveness]. HNO 2000;48(8):589-597.
219. Andersson G, Lyttkens L: A meta-analytic review of psychological treatments for tinnitus. Br J Audiol 1999;33(4):201-210.
220. Dobie RA: A review of randomized clinical trials in tinnitus. Laryngoscope 1999;109(8):1202-1211.
221. Goebel G, Hiller W: Tinnitus-Fragebogen (TF). Ein Instrument zur Erfassung von Belastung und Schweregrad bei Tinnitus. Göttingen Bern Toronto Seatlle, Hogrefe, 1998.
222. Delb W, D‘Amelio R, Archonti C, Schonecke O: Tinnitus. Ein Manual zur Tinnitus-Retrainingtherapie. Göttingen Bern Toronto Seattle, Hogrefe-Verlag, 2002.
223. Hesse G, Biesinger E, Greimel KV, Laubert A, Nelting M, Schaaf H, von Wedel H: Retraining und Tinnitustherapie. Stuttgart, New York, Georg Thieme Verlag, 1999.
224. Zenner HP, Zalaman IM: Cognitive tinnitus sensitization: behavioral and neurophysiological aspects of tinnitus centralization. Acta Otolaryngol 2004;124(4):436-439.
225. Greimel KV, Biesinger E: [Psychological principles in the treatment of tinnitus patients]. HNO 1999;47(2):130-134.
226. Kroener-Herwig B: Psychologische Behandlung des chronischen Tinnitus. Weinheim, Beltz, Psychologie Verlags Union, 1997.
227. Kroner-Herwig B, Hebing G, Rijn-Kalkmann U, Frenzel A, Schilkowsky G, Esser G: The management of chronic tinnitus--comparison of a cognitive-behavioural group training with yoga. J Psychosom Res 1995;39(2):153-165.
228. Kroner-Herwig B, Frenzel A, Fritsche G, Schilkowsky G, Esser G: The management of chronic tinnitus: comparison of an outpatient cognitive-behavioral group training to minimal-contact interventions. J Psychosom Res 2003;54(4):381-389.
229. Weinaug P: [Spontaneous remission in sudden deafness]. HNO 1984;32(8):346-351.
230. Schuknecht HF: Sudden Deafness; Pathology of the Ear. Philadelphia, Lea & Febiger, 1993, pp 524-529.
231. Chen CY, Halpin C, Rauch SD: Oral steroid treatment of sudden sensorineural hearing loss: a ten year retrospective analysis. Otol Neurotol 2003;24(5):728-733.
232. Beecher HK: The powerful placebo. JAMA 1955;159:1602-1606.
233. Hrobjartsson A, Gotzsche P: Placebo interventions for all clinical conditions. Cochrane Database Syst Rev 2004;3: CD003974.
234. Hrobjartsson A, Gotzsche PC: Is the placebo powerless? Update of a systematic review with 52 new randomized trials comparing placebo with no treatment. J Intern Med 2004;256(2):91-100.
235. Desloovere C, Meyer-Breiting E, von IC: [Randomized double-blind study of therapy of sudden deafness: initial results]. HNO 1988;36(10):417-422.
236. Cinamon U, Bendet E, Kronenberg J: Steroids, carbogen or placebo for sudden hearing loss: a prospective double-blind study. Eur Arch Otorhinolaryngol 2001;258(9):477-480.
237. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF: Improving the quality of reporting of randomized controlled trials. The CONSORT

statement. JAMA 1996;276(8):637-639.
238. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gotzsche PC, Lang T: The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001;134(8):663-694.
239. Moher D, Schulz KF, Altman DG: The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001;357(9263):1191-1194.
240. Ah-See KW, Molony NC: A qualitative assessment of randomized controlled trials in otolaryngology. J Laryngol Otol 1998;112(5):460-463.
241. Baujat B, De Minteguiaga C, Lecanu JB, Herman P, Tran Ba Huy P: [Is sudden sensorineural hearing loss a therapeutic emergency? Early results in a prospective cohort of 136 patients]. Ann Otolaryngol Chir Cervicofac 2002;119(1):3-11.
242. Byl FM, Jr.: Sudden hearing loss: eight years‘ experience and suggested prognostic table. Laryngoscope 1984;94(5 Pt 1):647-661.
243. Edamatsu H, Hasegawa M, Oku T, Nigauri T, Kurita N, Watanabe I: Treatment of sudden deafness: carbon dioxide and oxygen inhalation and steroids. Clin Otolaryngol 1985;10(2):69-72.
244. Fetterman BL, Saunders JE, Luxford WM: Prognosis and treatment of sudden sensorineural hearing loss. Am J Otol 1996;17(4):529-536.
245. Hultcrantz E, Stenquist M, Lyttkens L: Sudden deafness: a retrospective evaluation of dextran therapy. ORL J Otorhinolaryngol Relat Spec 1994;56(3):137-142.
246. Kanzaki J, Taiji H, Ogawa K: Evaluation of hearing recovery and efficacy of steroid treatment in sudden deafness. Acta Otolaryngol Suppl 1988;456:31-6.:31-36.
247. Leunig A, Szeimies RM, Wilmes E, Gutmann R, Stolz W, Feyh J: [Clinical and electron microscopy study of sudden deafness treatment with the 10% HES 200/0.5 and pentoxifylline combination]. Laryngorhinootologie 1995;74(3):135-140.
248. Linssen O, Schultz-Coulon HJ: [Prognostic criteria in sudden deafness]. HNO 1997;45(1):22-29.
249. Maassen MM, Pfister M, Plontke S, Koitschev A, Vogler A, Lowenheim H: [Recovery of hearing: results of delayed medical treatment in patients with idiopathic sudden hearing loss]. HNO 2002;50(12):1062-1067.
250. Michel O, Jahns T, Joost-Enneking M, Neugebauer P, Streppel M, Stennert E: [The Stennert antiphlogistic-rheologic infusion schema in treatment of cochleovestibular disorders]. HNO 2000;48(3):182-188.
251. Michels E, Matzker J: [Sudden deafness and its therapy. Clinical study of 548 cases]. Laryngol Rhinol Otol (Stuttg) 1988;67(4):171-176.
252. Minoda R, Masuyama K, Habu K, Yumoto E: Initial steroid hormone dose in the treatment of idiopathic sudden deafness. Am J Otol 2000;21(6):819-825.
253. Mosnier I, Bouccara D, tassi-Dumont M, Sterkers O: [Treatments of idiopathic sudden sensorineural hearing loss: retrospective study of 144 cases]. Rev Laryngol Otol Rhinol (Bord) 1998;119(2):119-128.
254. Samim E, Kilic R, Ozdek A, Gocmen H, Eryilmaz A, Unlu I: Combined treatment of sudden sensorineural hearing loss with steroid, dextran and piracetam: experience with 68 cases. Eur Arch Otorhinolaryngol 2004;261(4):187-190.
255. Shiraishi T, Kubo T, Okumura S, Naramura H, Nishimura M, Okusa M, Matsunaga T: Hearing recovery in sudden deafness patients using a modified defibrinogenation therapy. Acta Otolaryngol Suppl 1993;501:46-50.:46-50.
256. Wilkins SA, Jr., Mattox DE, Lyles A: Evaluation of a „shotgun“ regimen for sudden hearing loss. Otolaryngol Head Neck Surg 1987;97(5):474-480.
257. Wissen I, Aziz MY: [Experiences in therapy of acute labyrinthine deafness with low-molecular dextran, pentoxifyllin and nicotinic acid]. Laryngol Rhinol Otol (Stuttg) 1981;60(7):361-363.
258. Zadeh MH, Storper IS, Spitzer JB: Diagnosis and treatment of sudden-onset sensorineural hearing loss: a study of 51 patients. Otolaryngol Head Neck Surg 2003;128(1):92-98.
259. Zastrow G, Arndt HJ: [Clinical aspects and therapy of sudden deafness. Data of a patient sample of the ear, nose, throat clinic of the Wiesbaden City Clinic 1974-1982]. Laryngol Rhinol Otol (Stuttg) 1987;66(5):237-241.
260. Nageris BI, Ulanovski D, Attias J: Magnesium treatment for sudden hearing loss. Ann Otol Rhinol Laryngol 2004;113(8):672-675.
261. Ganzer, U, Albegger, K. W., Arnold, W., Biesinger, E., Brusis, T., Jahnke, K., Jaumann, M. P., Klemm, E., Koch, U., Lamm, K., Lenarz, T., Michel, O., Mösges, R., Probst, R., Strutz, J., Suckfull, M., Vasseur, M., Westhofen, M., and Zenner, H. P. Leitlinie Hörsturz der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie. Ganzer, U. AWMF online, Nr.017/010 . 2004.
262. Eibach H, Borger U: [Therapeutic results in acute acoustic trauma]. Arch Otorhinolaryngol 1980;226(3):177-186.
263. Pilgramm M: [Hemodilution therapy of acute inner ear damage]. Acta Med Austriaca 1991;18 Suppl 1:60-2.
264. Pilgramm M, Schafer A, Schumann K: [Efficacy of naftidrofurylhydrogenoxalate (Dusodril) as adjunctive therapy of patients with acute acoustic trauma. A controlled double-blind study]. Laryngol Rhinol Otol (Stuttg) 1986;65(7):381-383.
265. Pilgramm M, Schumann K: Hyperbaric oxygen therapy for acute acoustic trauma. Arch Otorhinolaryngol 1985;241(3):247-257.

266. Pilgramm M: Clinical and animal experiment studies to optimise the therapy for acute acoustic trauma. Scand Audiol Suppl 1991;34:103-22.:103-122.
267. Maurer J, Mann WJ, Amedee RG: Calcium channel blockers for prevention of noise trauma in otologic surgery. J La State Med Soc 1998;150(9):400-405.
268. Attias J, Weisz G, Almog S, Shahar A, Wiener M, Joachims Z, Netzer A, Ising H, Rebentisch E, Guenther T: Oral magnesium intake reduces permanent hearing loss induced by noise exposure. Am J Otolaryngol 1994;15(1):26-32.
269. Gacek RR, Gacek MR: Advances in Otorhinolranygology Vol. 60: Viral neuropathies in the temopral bone. Karger, 2002.
270. Westerlaken BO, Stokroos RJ, Dhooge IJ, Wit HP, Albers FW: Treatment of idiopathic sudden sensorineural hearing loss with antiviral therapy: a prospective, randomized, double-blind clinical trial. Ann Otol Rhinol Laryngol 2003;112(11):993-1000.
271. Stokroos RJ, Albers FW, Tenvergert EM: Antiviral treatment of idiopathic sudden sensorineural hearing loss: a prospective, randomized, double-blind clinical trial. Acta Otolaryngol 1998;118(4):488-495.
272. Tucci DL, Farmer JC, Jr., Kitch RD, Witsell DL: Treatment of sudden sensorineural hearing loss with systemic steroids and valacyclovir. Otol Neurotol 2002;23(3):301-308.
273. Uri N, Doweck I, Cohen-Kerem R, Greenberg E: Acyclovir in the treatment of idiopathic sudden sensorineural hearing loss. Otolaryngol Head Neck Surg 2003;128(4):544-549.
274. McCabe BF: Autoimmune sensorineural hearing loss. Ann Otol Rhinol Laryngol 1979;88(5 Pt 1):585-589.
275. Gloddek B, Arnold W: Clinical and experimental studies of autoimmune inner ear disease. Acta Otolaryngol Suppl 2002;(548):10-14.
276. Ryan AF, Harris JP, Keithley EM: Immune-mediated hearing loss: basic mechanisms and options for therapy. Acta Otolaryngol Suppl 2002;(548):38-43.
277. Solares CA, Hughes GB, Tuohy VK: Autoimmune sensorineural hearing loss: an immunologic perspective. J Neuroimmunol 2003;138(1-2):1-7.
278. Lautermann J, Dehne N, Schacht J, Jahnke K: [Aminoglycoside- and cisplatin-ototoxicity: from basic science to clinics]. Laryngorhinootologie 2004;83(5):317-323.
279. Huang W, Chen Y, Zha D, Qiu J, Wang J, Sha S, Schacht J: Prevention of Aminoglycoside-Induced Hearing Loss by Aspirin: Preliminary Data From a Clinical Study. Assos Res Otolaryngol Abs 2002;262.
280. Wimmer C, Mees K, Stumpf P, Welsch U, Reichel O, Suckfull M: Round window application of D-methionine, sodium thiosulfate, brain-derived neurotrophic factor, and fibroblast growth factor-2 in cisplatin-induced ototoxicity. Otol Neurotol 2004;25(1):33-40.
281. el Sammaa M, Linthicum FH, Jr., House HP, House JW: Calcitonin as treatment for hearing loss in Paget‘s disease. Am J Otol 1986;7(4):241-243.
282. Lando M, Hoover LA, Finerman G: Stabilization of hearing loss in Paget‘s disease with calcitonin and etidronate. Arch Otolaryngol Head Neck Surg 1988;114(8):891-894.
283. Zenner HP: Implantable hearing devices: an introduction; In: Jahnke K (ed): Middle ear surgery - recent advances and future directions. Stuttgart, New York, Thieme, 2004, pp 141-160.
284. Cremers CWRJ, Smith RJH: Genetic Hearing Impairment. Basel, Karger, 2002.
285. Pfister, M. and Blin, N. Genetik der HNO-Krankheiten. Medizinische Genetik 14[1], 5-57. 2002.
286. Kennedy DW, Hoffer ME, Holliday M: The effects of etidronate disodium on progressive hearing loss from otosclerosis. Otolaryngol Head Neck Surg 1993;109(3 Pt 1):461-467.
287. Cheung BM, Lauder IJ, Lau CP, Kumana CR: Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol 2004;57(5):640-651.
288. Preyer S, Baisch A, Bless D, Gummer AW: Distortion product otoacoustic emissions in human hypercholesterolemia. Hear Res 2001;152(1-2):139-151.
289. Biesinger E: Die Behandlung von Ohrgeräuschen. Stuttgart, Trias, 2002.
290. Feldmann H, Lenarz T, von Wedel H: Tinnitus.Grundlagen einer rationalen Diagnostik und Therapie. 2. ed, Stuttgart, New York, Georg Thieme Verlag Stuttgart, 1998.
291. Goebel G: Ohrgeräusche erträglich machen. Heidelberg, Urban & Vogel, 2001.
292. Goebel G: Tinnitus und Hyperakusis. Göttingen, Hogrefe, 2003.
293. Schaaf H, Holtmann H: Psychotherapie bei Tinnitus. Stuttgart, Schattauer Verlag, 2002.
294. Lenarz, T., Arnold, W., Biesinger, E., Brinkmann, U., Edlinger, H., Ehrenberger, K., Goebel, G., Greimel, K. V., Knör, H., Mackinger, H., Malisa, E., Moser, M., Walger, M., von Wedel, H., and ADANO. Leitlinie Tinnitus der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals- Chirurgie. Lenarz, T. AMWF online 017/064 . 27-5-1998.
295. Andersson G, Baguley D, McKenna L: Tinnitus: A Multidisciplinary Approach. London, Whurr Publishers, 2004.
296. Jastreboff PJ, Hazell JW: Tinnitus Retraining Therapy: Implementing the Neurophysiological Model. Cambridge, Cambridge university Press, 2004.
297. Jastreboff PJ, Gray WC, Mattox DE: Tinnitus and Hyperacusis; In: Cummings C, Frederickson JM, Harker LA, Krause CJ, Richardson MA, Schuller DE (eds):

Otolaryngology-Head and Neck Surgery. St. Louis, Mosby, 1999.
298. Tyler RS: Tinnitus Handbook. Singular Publishing Group Inc., 2000.
299. Ehrenberger K, Felix D: Receptor pharmacological models for inner ear therapies with emphasis on glutamate receptors: a survey. Acta Otolaryngol 1995;115(2):236-240.
300. Simpson JJ, Davies WE: Recent advances in the pharmacological treatment of tinnitus. Trends Pharmacol Sci 1999;20(1):12-18.
301. Denk DM, Heinzl H, Franz P, Ehrenberger K: Caroverine in tinnitus treatment. A placebo-controlled blind study. Acta Otolaryngol 1997;117(6):825-830.
302. Nelting M: Hyperakusis. Stuttgart, New York, Ggeorg Thieme Verlag, 2002.
303. Koehn W, Nickol HJ: [Sudden deafness--on the age dependence of therapy results with reference to naftidrofuryl (Dusodril)]. HNO 1985;33(1):36-39.
304. Nickisch A, Heinemann M, Gross M: [Drug therapy in sensorineural hearing loss in childhood]. Laryngol Rhinol Otol (Stuttg) 1987;66(12):664-666.
305. Nickisch A, Heinemann M, Gross M: [Different forms of drug therapy for progressive sensorineural hearing loss in childhood]. Laryngol Rhinol Otol (Stuttg) 1988;67(10):498-500.
306. Beutter P, Guinard F, Jalbert D, Marsac A, Morin R, Sauvage JP, Soudant J: [Value of the administration of trimetazidine associated with hemodilution in the treatment of sudden deafness. Report of a multicenter study]. Ann Otolaryngol Chir Cervicofac 1990;107(5):345-350.
307. Poser R, Hirche H: [Randomized double-blind study of therapy of sudden deafness. Low molecular weight dextran + naftidrofuryl vs. low molecular weight dextran + placebo]. HNO 1992;40(10):396-399.
308. Dauman R, Poisot D, Cros AM, Zennaro O, Bertrand B, Duclos JY, Esteben D, Milacic M, Boudey C, Bebear JP: [Sudden deafness: a randomized comparative study of 2 administration modalities of hyperbaric oxygenotherapy combined with naftidrofuryl]. Rev Laryngol Otol Rhinol (Bord) 1993;114(1):53-58.
309. Sano H, Okamoto M, Hirayama M, Ono Y, Nitta M: [Hearing recovery in sudden deafness with profound hearing loss]. Nippon Jibiinkoka Gakkai Kaiho 1998;101(6):836-840.
310. Fujino M, Hisashi K, Yashima N, Takeshita M, Fujiwara Y, Chujo K, Nakagawa T, Komune S, Komiyama S: Treatment of sudden sensorineural hearing loss with a continuous epidural block. Eur Arch Otorhinolaryngol 1999;256 Suppl 1:S18-21.
311. Gordin A, Goldenberg D, Golz A, Netzer A, Joachims HZ: Magnesium: a new therapy for idiopathic sudden sensorineural hearing loss. Otol Neurotol 2002;23(4):447-451.
312. Joachims HZ, Segal J, Golz A, Netzer A, Goldenberg D: Antioxidants in treatment of idiopathic sudden hearing loss. Otol Neurotol 2003;24(4):572-575.
313. Giger HL: [Therapy of sudden deafness with O2/CO2 inhalation]. HNO 1979;27(3):107-109.
314. Goto F, Fujita T, Kitani Y, Kanno M, Kamei T, Ishii H: Hyperbaric oxygen and stellate ganglion blocks for idiopathic sudden hearing loss. Acta Otolaryngol 1979;88(5-6):335-342.
315. Dauman R, Cros AM, Poisot D: (Treatment of sudden deafness: first results of a comparative study). J Otolaryngol 1985;14(1):49-56.
316. Pilgramm M, Vestner HJ, Schumann K: [Low-molecular-weight hydroxyethyl starch or low-molecular-weight dextran in acute inner ear disorders? A randomized comparative study]. Laryngol Rhinol Otol (Stuttg) 1986;65(7):377-380.
317. Laskawi R, Schrader B, Schroder M, Poser R, von der Brelie R: [Therapy of sudden deafness--naftidrofuryl (Dusodril) and pentoxifylline (Trental) compared]. Laryngol Rhinol Otol (Stuttg) 1987;66(5):242-245.
318. Friedrich G, Ott E: [Prospective randomized study on the comparative effect between 10% HES 200/0.5 and 6% HES 200/0.5 in patients with hearing loss]. Laryngorhinootologie 1991;70(12):670-674.
319. Kanzaki J, Inoue Y, Ogawa K, Fukuda S, Fukushima K, Gyo K, Yanagihara N, Hoshino T, Ishitoya J, Toriyama M, Kitamura K, Murai K, Nakashima T, Niwa H, Nomura Y, Kobayashi H, Oda M, Okamoto M, Shitara T, Sakagami M, Tono T, Usami S: Effect of single-drug treatment on idiopathic sudden sensorineural hearing loss. Auris Nasus Larynx 2003;30(2):123-127.
320. Sakata E, Nakazawa H, Iwashita N: [Therapy of tinnitus. Tympanic cavity infusion of lidocaine and steroid solution]. Auris Nasus Larynx 1984;11(1):11-18.
321. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, Hill S, Jaeschke R, Leng G, Liberati A, Magrini N, Mason J, Middleton P, Mrukowicz J, O'Connell D, Oxman AD, Phillips B, Schunemann HJ, Edejer TT, Varonen H, Vist GE, Williams JW, Jr., Zaza S: Grading quality of evidence and strength of recommendations. BMJ 2004;328(7454):1490.
322. Izumikawa M, Minoda R, Kawamoto K, Abrashkin KA, Swiderski DL, Dolan DF, Brough DE, Raphael Y. Auditory hair cell replacement and hearing improvement by Atoh1 gene therapy in deaf mammals. Nat Med. 2005 Feb 13; [Epub ahead of print]
323. Sage C, Huang M, Karimi K, Gutierrez G, Vollrath MA, Zhang DS, Garcia-Anoveros J, Hinds PW, Corwin JT, Corey DP, Chen ZY. Proliferation of functional hair cells in vivo in the absence of the retinoblastoma protein. Science. 2005 Feb 18;307(5712):1114-8
324. Trune DR, Wobig RJ, Kempton JB, Hefeneider SH. Steroid treatment improves cochlear function in the MRL.MpJ-Fas(lpr) autoimmune mouse. Hear Res. 1999;137(1-2):160-6.
325. Trune DR, Wobig RJ, Kempton JB, Hefeneider SH. Steroid treatment in young

MRL.MpJ-Fas(lpr) autoimmune mice prevents cochlear dysfunction. Hear Res. 1999;137(1-2):167-73.

326. Trune DR, Kempton JB, Kessi M. Aldosterone (mineralocorticoid) equivalent to prednisolone (glucocorticoid) in reversing hearing loss in MRL/MpJ-Fas1pr autoimmune mice. Laryngoscope. 2000;110(11):1902-6.
327. Gross ND, Kempton JB, Trune DR. Spironolactone blocks glucocorticoid-mediated hearing preservation in autoimmune mice. Laryngoscope. 2002;112(2):298-303.
328. Zenner HP. A Systematic Classification of Tinnitus Generator Mechanisms. Int Tinnitus J. 1998;4(2):109-113.
329. Plontke S, Siedow N, Hahn H, Wegener R, Zenner HP, Salt AN (2004) 1D- und 3D-Computer-Simulationen zur Versuchsplanung und –Interpretation bei pharmakokinetischen Studien am Innenohr nach lokaler Medikamentenapplikation. ALTEX 21, Suppl 3: 77-85